Jul 15, 2026 08:30AM
Jul 15, 2026 08:30AM
Apr 15, 2026 08:31AM
Apr 15, 2026 08:30AM
Apr 13, 2026 11:13AM
Jan 12, 2026 10:14AM
Dec 15, 2025 05:40PM Allogene retains control of cancer therapy after arbitration ruling
Dec 15, 2025 05:39PM
Nov 6, 2025 04:05PM
Nov 3, 2025 09:04AM
Aug 13, 2025 04:05PM
Aug 1, 2025 08:31AM
Aug 1, 2025 08:30AM
Jun 1, 2025 10:45AM Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
May 22, 2025 05:21PM
May 22, 2025 05:17PM
Apr 23, 2025 10:12AM
Apr 7, 2025 08:31AM
Apr 7, 2025 08:30AM
Mar 13, 2025 04:02PM
Feb 25, 2025 04:11PM Allogene Therapeutics (ALLO) Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
Feb 25, 2025 04:10PM
Feb 13, 2025 04:30PM
Feb 13, 2025 04:30PM
Jan 28, 2025 08:31AM
Jan 28, 2025 08:30AM
Jan 2, 2025 04:00PM
Nov 18, 2024 08:37AM Allogene Therapeutics (ALLO) Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergenc
Nov 18, 2024 08:30AM
Nov 7, 2024 04:02PM
Nov 7, 2024 10:00AM
Nov 7, 2024 10:00AM
Nov 5, 2024 09:10AM
Oct 30, 2024 08:14AM
Oct 29, 2024 08:30AM Allogene Therapeutics (ALLO) Receives FDA Regenerative Medicine Advanced Therapy Designation for ALLO-316
Oct 29, 2024 08:30AM
Sep 26, 2024 08:33AM
Sep 26, 2024 08:30AM
Aug 7, 2024 04:02PM
Jul 1, 2024 08:30AM
Jun 20, 2024 08:30AM
May 13, 2024 04:01PM Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
Apr 26, 2024 08:32AM
Apr 26, 2024 08:30AM
Apr 26, 2024 08:30AM
Mar 14, 2024 04:05PM
Mar 12, 2024 08:30AM
Mar 12, 2024 08:30AM
Jan 4, 2024 04:16PM Allogene Therapeutics (ALLO), Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3
Jan 4, 2024 04:15PM

326,531 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All